Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Klebsiella pneumoniae cell envelope receptors represent a complex array of surface structures, including outer membrane proteins (OMPs), lipopolysaccharides (LPS), and capsular polysaccharides (CPS), which are vital for the pathogen's structural integrity and interaction with its environment (Sugawara et al., 2016). These components function as essential gateways for nutrient acquisition and osmotic regulation, while also acting as potent virulence factors that shield the bacterium from host immune defenses and environmental stressors (Townsend et al., 2021). In clinical medicine, these receptors are critical pharmacological targets; for example, the LPS is the primary binding site for polymyxin antibiotics, and porins like OmpK35 and OmpK36 are the main entry points for beta-lactams such as carbapenems (Poirel et al., 2017; Pitout et al., 2015). Furthermore, these surface molecules serve as specific attachment sites for bacteriophages, making them central to the development of alternative therapeutic strategies like phage therapy (Townsend et al., 2021). However, the high plasticity of these receptors, characterized by frequent mutations or loss of expression, is a primary mechanism by which K. pneumoniae develops multi-drug resistance, posing a significant challenge to effective treatment (Pitout et al., 2015).
Drugs targeting these receptors work through several mechanisms: polymyxins bind to the lipid A component of LPS to disrupt membrane stability (Poirel et al., 2017); carbapenems enter the periplasm via porin channels to inhibit peptidoglycan synthesis (Sugawara et al., 2016); and siderophore-antibiotic conjugates like cefiderocol use active transport receptors for cellular entry (Wu et al., 2020). Bacteriophages utilize these surface molecules as specific docking sites for viral attachment and subsequent DNA injection (Townsend et al., 2021).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Klebsiella pneumoniae cell envelope receptors.